7
Participants
Start Date
December 31, 2015
Primary Completion Date
May 30, 2017
Study Completion Date
January 4, 2021
AR-42
AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
Johns Hopkins University, Baltimore
Mayo Clinic, Rochester
Stanford University, Stanford
Massachusetts Eye and Ear, Boston
Collaborators (1)
Johns Hopkins University
OTHER
Mayo Clinic
OTHER
Stanford University
OTHER
Ohio State University
OTHER
Nationwide Children's Hospital
OTHER
Massachusetts Eye and Ear Infirmary
OTHER